Stock 6472 BORA PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bora Pharmaceuticals Co., LTD.

Equities

6472

TW0006472004

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-06-03 pm EDT 		5-day change 1st Jan Change
749 TWD -2.35% Intraday chart for Bora Pharmaceuticals Co., LTD. +0.54% +17.21%
May. 14 Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 14 Bora Pharmaceuticals USA Inc. announced that it expects to receive $57 million in funding from Bora Pharmaceuticals Co., LTD. CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • With an enterprise value anticipated at 4.51 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BORA PHARMACEUTICALS CO., LTD. Stock Bora Pharmaceuticals Co., LTD.
+17.21% 2.33B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+41.86% 750B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 606B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.07% 356B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.75% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+6.35% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.42% 246B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-2.94% 213B
A+
NOVARTIS AG Stock Novartis AG
+10.89% 213B
B-
PFIZER, INC. Stock Pfizer, Inc.
+2.26% 167B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 6472 Stock
  4. Ratings Bora Pharmaceuticals Co., LTD.